HUTCHMED (China) vs Sinovac Biotech
HCM and SVA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How HCM and SVA compare
Sinovac Biotech grew revenue faster over the last twelve months (6.8% versus −13.0% for HUTCHMED (China)).
Sinovac Biotech scores higher on the StockData Score (6 against 5 for HUTCHMED (China)), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | HCM | SVA |
|---|---|---|
| Size and price | ||
| Share price | $14.90 | $6.47 |
| Change, 1 year | −2.5% | 0.00% |
| Change, 5 years | −51.5% | 0.00% |
| Beta (5Y) | 0.97 | 0.00 |
| Employees | 109 | 2,602 |
| StockData Score | ||
| Total score | 5 | 6 (better) |
| Valuation score | 0 | 0 |
| Growth score | 0 | 1 (better) |
| Performance score | 3 (better) | 0 |
| Health score | 2 | 5 (better) |
| Dividend score | 0 | 0 |
| Growth | ||
| Revenue growth (TTM) | −13.0% | 6.8% (better) |
| Revenue growth, 5Y average | 19.2% (better) | −5.4% |
| Net income growth (TTM) | 1111% | – |
| EPS growth (TTM) | 1200% (better) | −165% |
| Profitability | ||
| Gross margin | 38.7% | 67.9% (better) |
| Operating margin | −7.1% (better) | −127% |
| Net margin | 83.3% | – |
| FCF margin | −14.4% (better) | −145% |
| Return on equity | 36.7% | – |
| Financial health | ||
| Debt / equity | 0.09 (better) | 0.00 |
| Interest coverage | −13.7× | – |
| Current ratio | 5.64 (better) | 4.59 |
| Piotroski F-score | 4 | – |
| Dividends and buybacks | ||
| Years of dividend growth | – | 0 |
| Ownership | ||
| Held by institutions | 0.51% | 14.6% |
| Held by insiders | 0.44% | 65.7% |
| Short interest, % of float | – | 0.33% |
Go deeper
- HCM stock overview
- HCM income statement
- HCM valuation and score
- SVA stock overview
- SVA income statement
- SVA valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.